Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir Combined With Tocilizumab in COVID-19
NCT04310228Unknown
- Sponsor
- Peking University First Hospital
- Start
- Mar 2020
- Primary completion
- May 2020
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Favipiravir + Tocilizumab, Favipiravir and Tocilizumab (3 arms). Primary endpoint: Clinical cure rate at 3 months. Status: unknown.
02
Drugs
favipiravirtocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04310228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04310228.